Loading clinical trials...

Cognitive Consequences of an Activation of the Cortical Drive to Breath (VENTIPSY) | Clinical Trials | Clareo Health

COMPLETED

Cognitive Consequences of an Activation of the Cortical Drive to Breath (VENTIPSY)

Cognitive Consequences of an Activation of the Cortical Drive to Breath

NCT03095729•Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil

Summary

The purpose of the study is to measure the negative cognitive consequences of the ventilation under pathological or experimental cortical drive to breath.

Detailed Description

Cognitive capacities are measured on healthy subject submitted to inspiratory threshold loading, patients treated by chronic mechanical ventilation due to suffering Ondine syndrome or amyotrophic lateral sclerosis. The spontaneous breathing is compared to NIV breathing or inspiratory threshold loading.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Adults and non-vulnerable adults
•Fluent in French

Exclusion Criteria

•For patients:
•Total ventilatory dependency
•Coexistence of an other respiratory disease
•Alcohol and /or psychotropic consumption during the last 24 hours
•One or more episodes of acute respiratory failure during the past 6 months
•Serious cognitive deficiency or presence of fronto temporal dementia
•End-stage disease
•No affiliation to social security
•For healthy volunteers:
•Existing respiratory disease
+5 more criteria

Locations (1)

INSERM-UPC UMR_S 1158, Service de Pneumologie et Réanimation, GH Pitié-Salpêtrière

Paris, France

Key Dates

Start Date

April 26, 2017

Primary Completion Date

July 4, 2019

Completion Date

July 4, 2019

Last Updated

July 9, 2021

Enrollment

ACTUAL participants

Conditions

Ondine SyndromeHealthyAmyotrophic Lateral Sclerosis

Interventions

Neuropsychological tests

OTHER

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT07310264

Healthy Volunteers (HV)Parkinson's Disease (PD)

View study

RECRUITINGPHASE1/PHASE2

Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder.

NCT06290258

Autism Spectrum DisorderGastrointestinal Diseases+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 9, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Cognitive Consequences of an Activation of the Cortical Drive to Breath (VENTIPSY)

Inclusion Criteria

Exclusion Criteria

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder.

Collection of Data and Samples From Healthy Donors for Use in Translational Research

A New Portable Device for Non-invasive Ventilatory Support

Turkish Validity and Reliability Study of PRevention of Toxic Chemicals in the Environment for Children Tool

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases